Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
VixiMed AB
AB
Active
Org 5568033087
Kungsgatan 62, 753 18
Uppsala
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2010 · 16 years old
1 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
VixiMed AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
4M
3M
2M
1M
0M
2020: 3M
3M
2020
2021: 2M (-33% vs 2020)
2M
-33%
2021
2022: 2M (0% vs 2021)
2M
0%
2022
2023: 2M (0% vs 2022)
2M
0%
2023
2024: 2M (0% vs 2023)
2M
0%
2024
EBITDA
SEK millions
0M
0M
0M
-1M
-1M
2020: 0M
0M
2020
2021: 0M
0M
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
1 875
2 084
1 869
2 377
2 694
Staff expenses
−1 056
−1 042
—
—
—
EBITDA
−95
222
−338
0
359
Depreciation & amort.
—
−1
−11
−15
−15
EBIT
−95
221
−349
−15
344
Net financials
7
4
—
—
−1
Profit before tax
−88
225
−315
37
256
Tax
17
−66
39
−37
−73
Net profit
−71
159
−276
0
183
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
1 093
1 219
1 085
1 561
1 903
Equity
638
809
650
926
987
Long-term debt
—
—
0
0
0
Short-term debt
455
410
435
600
829
Total debt
455
410
435
600
829
Financial ratios
5-year trend
EBITDA margin
−5,1 %
This company
15,8 %
Market median
This company
Market median
132% below market
2020
2024
Equity ratio
58,4 %
This company
38,2 %
Market median
This company
Market median
53% above market
2020
2024
Return on equity
−11,2 %
This company
18,4 %
Market median
This company
Market median
161% below market
2020
2024
Net profit margin
−3,8 %
This company
8,1 %
Market median
This company
Market median
147% below market
2020
2024
Asset turnover
1,72×
This company
1,12×
Market median
This company
Market median
54% above market
2020
2024
Debt / equity
0,71×
This company
0,62×
Market median
This company
Market median
15% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on VixiMed AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
